• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket

    1/8/24 8:20:16 AM ET
    $AIMD
    $AMPE
    $AREN
    $BREA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email

    Shares of LumiraDx Limited (NASDAQ:LMDX) shares fell sharply in pre-market trading.

    LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.

    LumiraDx shares dipped 30.5% to $0.0239 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Harpoon Therapeutics, Inc.(NASDAQ:HARP) gained 98.6% to $20.95 in pre-market trading. Bloomberg reported that Merck is in advanced talks to buy Harpoon Therapeutics for $23 per share.
    • Vincerx Pharma, Inc. (NASDAQ:VINC) shares rose 56.3% to $1.86 in pre-market trading after the company announced compelling clinical efficacy of enitociclib in combination with venetoclax and prednisone in lymphoma.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) shares gained 46.6% to $2.48 in pre-market trading after gaining 7% on Friday.
    • Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) shares gained 36.5% to $3.40 in pre-market trading after jumping over 10% on Friday.
    • Vision Marine Technologies Inc. (NASDAQ:VMAR) shares climbed 30.4% to $1.24 in pre-market trading.
    • Heron Therapeutics, Inc. (NASDAQ:HRTX) shares rose 14.1% to $2.02 in pre-market trading. Heron Therapeutics announced a five-year distribution partnership with CrossLink Life Sciences to expand promotional effort for ZYNRELEF.
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) gained 12.4% to $2.00 in pre-market trading after falling around 8% on Friday.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) shares rose 11.8% to $0.6060 in pre-market trading. NanoString's CosMx SMI achieved whole transcriptome imaging at single-cell resolution.
    • eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) gained 9.2% to $0.5799 in pre-market trading.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) gained 8.8% to $0.1799 in pre-market trading. Heart Test Laboratories received decision to grant European Patent "Electrocardiogram-Based Assessment of Diastolic Function (Using Machine-Learned Computational Models).

    Losers

    • Banzai International, Inc. (NASDAQ:BNZI) shares fell 18.3% to $2.10 in pre-market trading. Banzai shares jumped around 55% on Friday after the company signed an LOI to acquire IGLeads.
    • The Arena Group Holdings, Inc. (NYSE:AREN) shares fell 17.2% to $1.78 in pre-market trading after dipping 17% on Friday.
    • Spirit AeroSystems Holdings, Inc. (NYSE:SPR) shares fell 16.4% to $26.53 in pre-market trading. The FAA ordered the temporary grounding of certain Boeing 737 Max 9 aircraft operated by U.S. Airlines or in U.S. territory.
    • Charge Enterprises, Inc. (NASDAQ:CRGE) shares fell 14.8% to $0.0793 in pre-market trading after dipping around 11% on Friday.
    • Safe and Green Development Corporation (NASDAQ:SGD) shares fell 14.3% to $1.74 in pre-market trading after jumping 49% on Friday.
    • Future FinTech Group Inc. (NASDAQ:FTFT) shares fell 13.4% to $1.23 in pre-market trading after dipping 22% on Friday.
    • Sharps Technology, Inc. (NASDAQ:STSS) fell 11.1% to $0.40 in pre-market trading after jumping 12% on Friday.
    • Ainos, Inc. (NASDAQ:AIMD) shares fell 11% to $2.44 in pre-market trading after jumping over 58% on Friday.
    • Brera Holdings PLC (NASDAQ:BREA) fell 10.1% to $0.6566 in pre-market trading.

     

    Now Read This: Commercial Metals, Boot Barn And 3 Stocks To Watch Heading Into Monday

    Get the next $AIMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIMD
    $AMPE
    $AREN
    $BREA

    CompanyDatePrice TargetRatingAnalyst
    The Arena Group Holdings Inc.
    $AREN
    7/21/2025$10.00Buy
    Lake Street
    Heron Therapeutics Inc.
    $HRTX
    6/9/2025$6.00Buy
    H.C. Wainwright
    Spirit Aerosystems Holdings Inc.
    $SPR
    6/20/2024Buy → Hold
    The Benchmark Company
    Heron Therapeutics Inc.
    $HRTX
    6/13/2024$7.00Buy
    Rodman & Renshaw
    Heron Therapeutics Inc.
    $HRTX
    4/23/2024$6.00Overweight
    CapitalOne
    Heron Therapeutics Inc.
    $HRTX
    3/13/2024$4.00 → $5.00Buy
    Needham
    Spirit Aerosystems Holdings Inc.
    $SPR
    2/8/2024$27.00 → $35.00Market Perform → Outperform
    TD Cowen
    Spirit Aerosystems Holdings Inc.
    $SPR
    1/17/2024$39.00Buy
    Citigroup
    More analyst ratings

    $AIMD
    $AMPE
    $AREN
    $BREA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMPE
    $AREN
    $BREA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Forbes William P

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    4/21/26 11:15:26 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Collard Craig A

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    4/21/26 9:41:20 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Duarte Ira

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    4/21/26 9:13:37 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIMD
    $AMPE
    $AREN
    $BREA
    SEC Filings

    View All

    SEC Form PRE 14A filed by Heron Therapeutics Inc.

    PRE 14A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

    4/20/26 5:13:40 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form QUALIF filed by HeartSciences Inc.

    QUALIF - HeartSciences Inc. (0001468492) (Filer)

    4/20/26 12:15:02 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 253G2 filed by HeartSciences Inc.

    253G2 - HeartSciences Inc. (0001468492) (Filer)

    4/17/26 5:00:12 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $AIMD
    $AMPE
    $AREN
    $BREA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on The Arena Group with a new price target

    Lake Street initiated coverage of The Arena Group with a rating of Buy and set a new price target of $10.00

    7/21/25 8:46:54 AM ET
    $AREN
    EDP Services
    Technology

    H.C. Wainwright initiated coverage on Heron Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $6.00

    6/9/25 7:51:39 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spirit Aerosystems downgraded by The Benchmark Company

    The Benchmark Company downgraded Spirit Aerosystems from Buy to Hold

    6/20/24 7:39:08 AM ET
    $SPR
    Military/Government/Technical
    Industrials

    $AIMD
    $AMPE
    $AREN
    $BREA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Arena Group to Host First Quarter 2026 Financial Results Conference Call on Friday, May 8, 2026

    Company Invites Shareholders to Submit Questions in Advance The Arena Group Holdings, Inc. (NYSE:AREN), the brand, data and IP company that builds, acquires and scales high-performing digital assets—home to many of the nation's most recognizable brands including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, ShopHQ and more—today announced that it will release its financial results for the first quarter ended March 31, 2026, on Friday, May 8, 2026, in advance of the open of the market. Conference Call and Webcast Details Paul Edmondson, The Arena Group's Chief Executive Officer and Geoffrey Wait, Principal Financial Officer will host a conference call and live webcast to rev

    4/24/26 8:30:00 AM ET
    $AREN
    EDP Services
    Technology

    Vision Marine Technologies Accelerates Operational Transformation with NVG Segment Near EBITDA Breakeven and Significant Balance Sheet Improvements

    MONTREAL, April 15, 2026 /PRNewswire/ -- Vision Marine Technologies Inc. (NASDAQ:VMAR) ("Vision Marine" or the "Company"), a company specializing in high-voltage marine propulsion and a vertically integrated marine retail platform, yesterday reported financial results for the three-month and six-month periods ended February 28, 2026, highlighting rapid execution and significant operational improvements across its Nautical Ventures Group Inc. ("NVG") platform. Since the acquisition of NVG on June 20, 2025, the Company has delivered substantial improvements in working capital effi

    4/15/26 6:00:00 AM ET
    $VMAR
    Marine Transportation
    Industrials

    HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting

    Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company") a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the "Annual Meeting") which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the

    4/14/26 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $AIMD
    $AMPE
    $AREN
    $BREA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ruemler Timothy James increased direct ownership by 294% to 40,218 units (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:45:47 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Crescenzo Andrew R. bought $256,400 worth of Option (40,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:34 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Director Monroe Jason L. bought $512,800 worth of Option (80,000 units at $6.41) (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    8/26/25 9:24:36 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $AIMD
    $AMPE
    $AREN
    $BREA
    Leadership Updates

    Live Leadership Updates

    View All

    FTFT Announces Agreement with S1Quant to Explore the New Blue Ocean of Compliant Cryptocurrency Asset Management

    NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Future FinTech Group Inc. (NASDAQ:FTFT, ", Future FinTech", , ", FTFT", , or the ", Company", )), a comprehensive financial and digital technology service provider, today announced that on December 29, 2025, its wholly-owned subsidiary, FTFT International Securities and Futures Limited ("FTFT Securities"), signed a Letter of Intent for Strategic Cooperation agreement (the "Agreement") with S1Quant in the field of cryptocurrency asset management. The two parties have agreed to join hands to establish long-term, in-depth cooperation in the field of cryptocurrency asset management and jointly promote the development of a compliant and professional cryptocu

    1/5/26 8:30:00 AM ET
    $FTFT
    Real Estate

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wall Street Finds Its Solmate: Brera Holdings PLC (NASDAQ: BREA) Announces Oversubscribed $300 Million Private Placement to Fund Establishment of Solana Digital Asset Treasury Backed by Ark Invest and UAE Investors

    Brera Holdings PLC ("Brera Holdings") (NASDAQ:BREA) will become Solmate, a Solana-based digital asset treasury ("DAT") and crypto infrastructure company.The PIPE is sponsored by UAE-based Pulsar Group, a strategic investment and advisory firm specializing in virtual assets, emerging technologies and blockchain.Solmate intends to drive shareholder value through accumulation and staking of $SOL, and new revenue streams from cutting-edge Solana staking infrastructure.Digital asset treasury pioneer Marco Santori will be installed as Solmate CEO; economics luminary and Solana advocate Dr. Arthur Laffer and early Solana investor RockawayX CEO Viktor Fischer to serve on the Solmate Board of Dire

    9/18/25 9:30:00 AM ET
    $BREA
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AIMD
    $AMPE
    $AREN
    $BREA
    Financials

    Live finance-specific insights

    View All

    The Arena Group to Host First Quarter 2026 Financial Results Conference Call on Friday, May 8, 2026

    Company Invites Shareholders to Submit Questions in Advance The Arena Group Holdings, Inc. (NYSE:AREN), the brand, data and IP company that builds, acquires and scales high-performing digital assets—home to many of the nation's most recognizable brands including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, ShopHQ and more—today announced that it will release its financial results for the first quarter ended March 31, 2026, on Friday, May 8, 2026, in advance of the open of the market. Conference Call and Webcast Details Paul Edmondson, The Arena Group's Chief Executive Officer and Geoffrey Wait, Principal Financial Officer will host a conference call and live webcast to rev

    4/24/26 8:30:00 AM ET
    $AREN
    EDP Services
    Technology

    The Arena Group and Playwire Partner to Bring High-Impact Ad Inventory to Scale

    The Arena Group Holdings, Inc. (NYSE:AREN), the brand, data and IP company home to many of the most recognizable brands including TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, ShopHQ and more, today announced its partnership with Playwire, the ad monetization platform for digital publishers, bringing scale to high-impact advertising inventory. Through the partnership, Playwire's direct sales team has the ability to sell Flex Suite advertising units across The Arena Group's portfolio of brands. The Flex Suite is Playwire's exclusive set of high-impact advertising formats. It uses code-on-page technology to provide custom placements that go beyond the capabilities of standard pro

    4/6/26 12:11:00 PM ET
    $AREN
    EDP Services
    Technology

    The Arena Group Reports Q4 and Full Year 2025 Results, Marking First Full Year of Positive Net Income and Major Debt Reduction

    Revenue Diversification, Commerce Expansion and Disciplined Operations Continue to Fuel Growth and Scale in Face of Industry Volatility The Arena Group Holdings, Inc. (NYSE:AREN) ("The Arena Group" or "Arena"), a brand, data, and IP company home to many of the nation's most recognizable brands, including Parade, TheStreet, Men's Journal, Athlon Sports, ShopHQ and the Adventure Network (including Surfer, Powder, Bike Magazine and more), today announced financial results for the three months ending December 31, 2025 ("Q4 2025") and the year ended December 31, 2025 ("FY 2025"). Financial Highlights for Q4 2025: Fourth quarter revenue was $28.2 million, compared to $36.2 million in Q4 20

    3/16/26 4:05:00 PM ET
    $AREN
    EDP Services
    Technology

    $AIMD
    $AMPE
    $AREN
    $BREA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Spirit Aerosystems Holdings Inc.

    SC 13G/A - Spirit AeroSystems Holdings, Inc. (0001364885) (Subject)

    11/14/24 5:12:55 PM ET
    $SPR
    Military/Government/Technical
    Industrials